Published in Can J Cardiol on May 15, 2006
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. Can J Cardiol (2007) 2.32
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J (2007) 1.72
How evidence-based are the recommendations in evidence-based guidelines? PLoS Med (2007) 1.60
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2007) 1.49
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Adding "value" to clinical practice guidelines. Can Fam Physician (2007) 1.24
Improving clinician self-efficacy does not increase asthma guideline use by primary care clinicians. Acad Pediatr (2012) 1.11
Underrepresentation of individuals 80 years of age and older in chronic disease clinical practice guidelines. Can Fam Physician (2011) 1.09
The 2007 Canadian Hypertension Education Program recommendations: the scientific summary - an annual update. Can J Cardiol (2007) 1.02
Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP). Can J Cardiol (2008) 1.01
Do beta-blockers have a role in treating hypertension? Yes. Can Fam Physician (2007) 1.01
Antihypertensive medication use by recently diagnosed hypertensive Canadians. Can J Cardiol (2007) 0.98
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf (2009) 0.94
Drug management for hypertension in type 2 diabetes in family practice. Can Fam Physician (2009) 0.92
AGREEing on Canadian cardiovascular clinical practice guidelines. Can J Cardiol (2008) 0.88
Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol (2010) 0.87
Optimal waist circumference cutoff values for the diagnosis of abdominal obesity in korean adults. Endocrinol Metab (Seoul) (2014) 0.87
Comprehensive cardiovascular risk management--what does it mean in practice? Vasc Health Risk Manag (2007) 0.86
An integrated approach to preventing cardiovascular disease: community-based approaches, health system initiatives, and public health policy. Risk Manag Healthc Policy (2010) 0.83
Management of atherothrombotic risk factors in high-risk Canadian outpatients. Can J Cardiol (2009) 0.82
Hypertension and type 2 diabetes: what family physicians can do to improve control of blood pressure--an observational study. BMC Fam Pract (2011) 0.79
More medications, fewer pills: combination medications for the treatment of hypertension. Can J Cardiol (2007) 0.78
Cardiovascular risk reduction via telehealth: a feasibility study. Can J Cardiol (2008) 0.78
Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. Curr Oncol (2009) 0.76
Pathophysiology and Medical Treatment of Carotid Artery Stenosis. Int J Angiol (2015) 0.75
Cholesterol lowering for secondary prevention: what statin dose should we use? Vasc Health Risk Manag (2007) 0.75
Impact of ethnic-specific guidelines for anti-hypertensive prescribing in primary care in England: a longitudinal study. BMC Health Serv Res (2014) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA (2003) 13.82
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet (2005) 9.00
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20
Awareness, treatment, and control of hypertension in Canada. Am J Hypertens (1997) 4.76
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 3.02
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens (2003) 2.71
Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ (2005) 2.54
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. Can J Cardiol (2004) 1.73
A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol (2000) 1.71
Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women: results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS). Arch Intern Med (2004) 1.51
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Can J Cardiol (2004) 1.46
Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol (2003) 1.43
The 2000 Canadian recommendations for the management of hypertension: Part one--therapy. Can J Cardiol (2001) 1.42
Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. Am J Cardiol (2003) 1.26
Active-control equivalence trials and antihypertensive agents. Am J Med (2001) 1.23
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail (2003) 1.20
Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy (2000) 1.11
Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol (2004) 0.92
Beta blockers for the treatment of primary hypertension. Lancet (2006) 0.79
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78
Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med (2015) 12.70
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet (2007) 8.68
Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med (2004) 8.07
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Predictors of new-onset kidney disease in a community-based population. JAMA (2004) 7.45
Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev (2010) 6.49
Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol (2006) 6.21
Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med (2005) 6.20
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 5.32
Less-tight versus tight control of hypertension in pregnancy. N Engl J Med (2015) 5.03
Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ (2006) 5.03
Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ (2007) 5.02
Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med (2006) 4.90
Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA (2003) 4.88
Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med (2005) 4.85
Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA (2004) 4.82
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care (2005) 4.78
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation (2003) 4.43
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke (2005) 4.07
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ (2007) 3.99
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ (2003) 3.85
Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation (2008) 3.76
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol (2007) 3.72
New evidence for stroke prevention: scientific review. JAMA (2002) 3.70
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ (2006) 3.62
Accuracy of administrative databases in identifying patients with hypertension. Open Med (2007) 3.56
Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med (2003) 3.43
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr (2008) 3.33
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26
GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension (2011) 3.26
Body mass index and mortality in heart failure: a meta-analysis. Am Heart J (2008) 3.25
Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA (2008) 3.25
A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med (2008) 3.21
Endothelial dysfunction. J Am Soc Nephrol (2004) 3.18
A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol (2007) 3.16
Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA (2002) 3.13
NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care (2008) 3.07
Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med (2007) 3.06
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int (2005) 3.03
Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol (2012) 3.03
Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA (2003) 3.03
Anesthetic management and outcome in patients during endovascular therapy for acute stroke. Anesthesiology (2012) 3.02
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol (2012) 2.94
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol (2005) 2.91
Methodology of the Interventional Management of Stroke III Trial. Int J Stroke (2008) 2.88
Results of the Ontario survey on the prevalence and control of hypertension. CMAJ (2008) 2.88
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol (2009) 2.82
Bronchodilators and acute cardiac death. Am J Respir Crit Care Med (1996) 2.80
Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke (2010) 2.79
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke (2006) 2.77
Validation of a case definition to define hypertension using administrative data. Hypertension (2009) 2.74
Preoperative hypernatremia predicts increased perioperative morbidity and mortality. Am J Med (2013) 2.69
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Job strain and risk of acute recurrent coronary heart disease events. JAMA (2007) 2.61
Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA (2010) 2.61
Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med (2012) 2.58
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ (2004) 2.55
Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med (2008) 2.55
Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med (2012) 2.54
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Transition from meeting abstract to full-length journal article for randomized controlled trials. JAMA (2006) 2.53
Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ (2005) 2.50
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int (2008) 2.46
Preoperative hyponatremia and perioperative complications. Arch Intern Med (2012) 2.42